Return-Path: <[log in to unmask]> Received: from coyote.dreamhost.com (coyote.dreamhost.com [66.33.216.128]) by mtain-mj01.r1000.mx.aol.com (Internet Inbound) with ESMTP id 2BAB6380000AD for <[log in to unmask]>; Thu, 15 Nov 2012 07:41:55 -0500 (EST) Received: from dreamhost.com (ip-66-33-206-8.dreamhost.com [66.33.206.8]) by coyote.dreamhost.com (Postfix) with ESMTP id EE803492A53D for <[log in to unmask]>; Thu, 15 Nov 2012 04:50:28 -0800 (PST) Date: Thu, 15 Nov 2012 04:41:48 -0800 From: "GMWatch" <[log in to unmask]> Subject: GMW: EU patents on GM chimps challenged To: [log in to unmask] Sender: [log in to unmask] Reply-To: "GMWatch" <[log in to unmask]> Precedence: list Content-type: text/plain; charset="utf-8" X-Mailer: DreamHost Mailing Lists X-DH-Mailer-ID: 1746802 X-Abuse-Info: http://dreamhost.com/tos.html X-Complaints-To: [log in to unmask] X-Bulkmail: 3.12 Message-Id: <[log in to unmask]> Content-Transfer-Encoding: quoted-printable x-aol-global-disposition: G x-aol-sid: 3039ac1d7b9550a4e3136d74 X-AOL-IP: 66.33.216.128 X-AOL-SPF: domain : dreamhost.com SPF : pass E.U. Patents on Transgenic Chimps Challenged Kai Kupferschmidt ScienceInsider, 13 November 2012 http://news.sciencemag.org/scienceinsider/2012/11/eu-patents-on-transgeni= c-chimps-.html Animal rights activists in Germany are contesting three patents on geneti= cally engineered chimpanzees granted this year by the European Patent Off= ice (EPO) in Munich. One of the challenges was filed today; the other two= will follow shortly, says Ruth Tippe, a spokesperson for a German advoca= cy group called No Patents on Life. "It is incomprehensible why the patent office would grant patents on thes= e animals," Tippe told ScienceInsider in a phone conversation minutes aft= er filing papers with EPO to oppose the first of the three patents. Patent number EP1456346 was granted to Intrexon, a company based in Black= sburg, Virginia, in February. In it, the company claims to have invented = a way to introduce into chimpanzees=E2=80=94as well as rats, rabbits, hor= ses, and other animals=E2=80=94a system to switch specific genes on or of= f. The animals are intended for pharmaceutical research. "The patent does= not show a clear medical benefit that can be weighed against the animals= ' suffering, and does not explain why chimpanzees are needed," Tippe says= . Instead of chimpanzees, other animals could be used, Tippe argues. "I'm a= gainst patents on any animals, but everything would be better than chimpa= nzees, our closest relatives." She worries that, at a time when using ape= s in research has become increasingly rare, patenting transgenic chimps c= ould create an economic incentive to use more of the animals. In a statement e-mailed to ScienceInsider, Intrexon did not elaborate on = the potential benefits of transgenic chimps, but it said that "geneticall= y modified chimpanzees are not an active area of research for Intrexon," = and that "approximately 99%" of the content of the European patent does n= ot relate to chimpanzees. Siobhan Yeats, an examiner of biotechnology patents at EPO, says the offi= ce routinely weighs animal suffering against expected benefits. If EPO ha= s no objection on these grounds, then that isn't noted in the patent file= , she says, "but that does not mean it wasn't looked at." And obtaining a= patent does not automatically grant people the right to use their invent= ion, Yeats says; depending on the country, laws and regulations may ban t= he use of genetically engineered chimps. "To use a drastic example: If yo= u get a patent on an atomic bomb, of course you cannot use it," she says. Intrexon now has 6 months to defend its patent. Then it will be reexamine= d by at least two new EPO officials before a decision is made to revoke, = maintain, or amend it. The company was granted another patent on chimpanzees genetically enginee= red to include a switch for certain genes this year, whereas Altor BioSci= ence, based in Miramar, Florida, was granted a patent on chimpanzees with= a humanized immune system. The latter could, for instance, be used to te= st antibody therapies. No Patents on Life, together with a German group c= alled Testbiotech and other nongovernmental organizations, plans to chall= enge these patents as well, Tippe says, using similar arguments. ................................................................ Website: http://www.gmwatch.org Profiles: http://www.powerbase.info/index.php/GM_Watch:_Portal Twitter: http://twitter.com/GMWatch Facebook: http://www.facebook.com/pages/GMWatch/276951472985?ref=3Dnf This email should only be sent to those who have asked to receive it. To unsubscribe, contact [log in to unmask], specifying which list you wish= to unsubscribe from. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - To unsubscribe from the IOWA-TOPICS list, send any message to: [log in to unmask] Check out our Listserv Lists support site for more information: http://www.sierraclub.org/lists/faq.asp To view the Sierra Club List Terms & Conditions, see: http://www.sierraclub.org/lists/terms.asp